Who are Chemotheraoy along's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): induction chemotherapy, epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil, Vinflunine plus Capecitabine, Short Course Adjuvent Chemotherapy, Tri-weekly cisplatin with RT, carboplatin/cisplatin-etoposide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chemotheraoy-along.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Chemotheraoy along — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotheraoy along (Chemotheraoy along) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapeutic agent. Area: Oncology.

phase 3 Chemotherapeutic agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Chemotheraoy along (Chemotheraoy along) — Fujian Medical University. Chemotheraoy along works by inhibiting cell division in rapidly proliferating cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Chemotheraoy along TARGET	Chemotheraoy along	Fujian Medical University	phase 3	Chemotherapeutic agent
induction chemotherapy	induction chemotherapy	Zhejiang Cancer Hospital	phase 3	Chemotherapeutic agent
epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil	epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil	Sun Yat-sen University	phase 3	anthracycline and antimetabolite chemotherapeutic agents
Vinflunine plus Capecitabine	Vinflunine plus Capecitabine	Pierre Fabre Medicament	phase 3	Platinum-based chemotherapeutic agent and fluoropyrimidine	DNA
Short Course Adjuvent Chemotherapy	Short Course Adjuvent Chemotherapy	Trans Tasman Radiation Oncology Group	phase 3	Chemotherapeutic agent
Tri-weekly cisplatin with RT	Tri-weekly cisplatin with RT	Korea Cancer Center Hospital	phase 3	chemotherapeutic agent
carboplatin/cisplatin-etoposide	carboplatin/cisplatin-etoposide	Shanghai Henlius Biotech	phase 3	platinum-based chemotherapeutic agents	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapeutic agent class)

All India Institute of Medical Sciences · 1 drug in this class
Fujian Medical University · 1 drug in this class
Trans Tasman Radiation Oncology Group · 1 drug in this class
Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chemotheraoy along — Competitive Intelligence Brief. https://druglandscape.com/ci/chemotheraoy-along. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab